11:06 AM EDT, 08/14/2024 (MT Newswires) -- Hamilton Thorne ( HTLZF ) , a company supplying the assisted reproductive technologies (ART) research and cell biology market, on Wednesday said second quarter net loss widened as revenues rose, but still missed forecast.

It reported net loss of near US$0.7 million or $0.00 basic and diluted EPS, which compares with a net loss of near $0.45 million or $0.00 for both the year before.

Revenue for the quarter rose 16%, to $19.1 million, compared to $16.44 million a year earlier. It missed a consensus forecast at Capital IQ of $19.4 million.

Hamilton Thorne ( HTLZF ) confirmed its guidance for 2024. it expects revenue of between $78 million and $82 million, equivalent to 10-15% organic growth for the full year.

The company continues to actively pursue multiple acquisition opportunities.

Hamilton Thorne ( HTLZF ) was up $0.01, to $2.08 on the Toronto Stock Exchange.

Price: 2.08, Change: +0.01, Percent Change: +0.48